Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for BELATACEPT
- Advancing Transplantation Outcomes in Children
- Subcutaneous Abatacept in Renal Transplant Recipients
- A Study of TCD601 in de Novo Renal Transplant Recipients
- Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction
- Novel Desensitization Protocol for Highly Sensitized Patients to Allow for Successful Kidney Transplantation. A Pilot Study.
- AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS
- A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation
- Abatacept Conversion in Kidney Transplantation
- A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, a
- Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)
- Daratumumab and Belatacept for Desensitization
- Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression
- Belatacept in De Novo Heart Transplantation
- Early Use of Long-acting Tacrolimus in Lung Transplant Recipients
- Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR)
- Immune Monitoring to Facilitate Belatacept Monotherapy
- Treg Modulation With CD28 and IL-6 Receptor Antagonists
- A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
- CNI Transient Replacement by Belatacept From 3 to 12 Months Post Transplantation in Patients With Early Graft Dysfunction
- Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization
- Tolerance by Engaging Antigen During Cellular Homeostasis
- Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation
- A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes
- Precision Medicine Offers Belatacept Monotherapy
- Belatacept (Nulojix) in Renal Transplant Recipient With Mild Immunologic Risk Factor: a Pilot Prospective Study.
- Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
- Bela 8 Week Dosing
- Belatacept Conversion in Proteinuric Kidney Transplant Recipients
- Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)
- Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy
- Belatacept 3 Month Post Transplant Conversion Study
- Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients
- Regimen Optimization Study
- Belatacept for Renal Transplant Recipients With Delayed Graft Function
- Belatacept in Kidney Transplantation of Moderately Sensitized Patients
- Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
- Efficacy of Belatacept in Reducing DSA
- Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)
- Belatacept Therapy for the Failing Renal Allograft
- Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression
- Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen
- Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function
- A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based
- Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients
- Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation
- Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers
- Abatacept as GVHD Prophylaxis Phase 2
- Belatacept Early Steroid Withdrawal Trial
- Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients
- Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores
- Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
- Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
- Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients
- A Belatacept Compassionate Use Study for Patients With a Kidney Transplant
- Belatacept Pharmacokinetic Trial in Renal Transplantation
- Subcutaneous Pharmacokinetics of Belatacept
- Belatacept Post Depletional Repopulation to Facilitate Tolerance
- Belatacept in Liver Transplant Recipients
- Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus
- LEA29Y (Belatacept) Emory Edmonton Protocol
- A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation
- A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
- Belatacept to Prevent Organ Rejection in Kidney Transplant Patients
- Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis
- Islet Transplantation Using Abatacept
- Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)
- Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
- Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney
Clinical trials list
click for details